Galapagos NV expected to post a loss of 83 cents a share - Earnings Preview

Lakefront Biotherapeutics NV

01/08/2023 12:01

* Galapagos NV  GLPG.AS   is expected to show a fall in
quarterly
revenue when it reports  results on August 3. 
    * The Malines (mechelen) Antwerpen-based  company is
expected to
report  a 6.8% decrease in revenue to €128.292 million from
€137.61 million a year ago, according to the mean estimate from
3 analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Galapagos NV is for
a
loss of 83 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 8
"hold" and no "sell" or "strong sell."  
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "Hold".​
    * Wall Street's median 12-month price target for Galapagos
NV is
€42​, above​ its last closing price of €38.08. ​​​

This summary was machine generated August 1 at 11:01 GMT.  All
figures in euros  unless otherwise stated